Year All202620252024202320222021202020192018201720162014201320112010 December 22, 2020 Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes December 11, 2020 Rhythm Pharmaceuticals Announces Appointments of Camille L. Bedrosian, M.D., and Lynn Tetrault, J.D., to its Board of Directors November 27, 2020 Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™ (setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency November 4, 2020 Rhythm Pharmaceuticals Announces New Clinical Data on Setmelanotide at ObesityWeek® 2020 November 2, 2020 Rhythm Pharmaceuticals Reports Third Quarter 2020 Financial Results October 30, 2020 Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trials of Setmelanotide in The Lancet Diabetes & Endocrinology October 28, 2020 Rhythm Pharmaceuticals Appoints Jennifer Chien as Executive Vice President, Head of North America September 14, 2020 Rhythm Pharmaceuticals Appoints Yann Mazabraud as Executive Vice President, Head of International September 9, 2020 Rhythm Pharmaceuticals to Present at Investor Conferences in September August 6, 2020 Rhythm Pharmaceuticals to Present Virtually at Canaccord Genuity 40th Annual Growth Conference
December 22, 2020 Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes
December 11, 2020 Rhythm Pharmaceuticals Announces Appointments of Camille L. Bedrosian, M.D., and Lynn Tetrault, J.D., to its Board of Directors
November 27, 2020 Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™ (setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency
November 4, 2020 Rhythm Pharmaceuticals Announces New Clinical Data on Setmelanotide at ObesityWeek® 2020
October 30, 2020 Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trials of Setmelanotide in The Lancet Diabetes & Endocrinology
October 28, 2020 Rhythm Pharmaceuticals Appoints Jennifer Chien as Executive Vice President, Head of North America
September 14, 2020 Rhythm Pharmaceuticals Appoints Yann Mazabraud as Executive Vice President, Head of International
August 6, 2020 Rhythm Pharmaceuticals to Present Virtually at Canaccord Genuity 40th Annual Growth Conference
